teva pharmaceuticals introduces the first generic glp-1 for weight loss Launches Drug Obesity Teva launches generic version of

Aim for 0.7 to 1.0 grams per pound of body weight daily

Based on our retrieved publications, 16 GLP-1RAs were identified, and taspoglutide was excluded because it was out of development due to strong gastrointestinal adverse effects

By: Kristin Brooks Managing Editor, Contract Pharma Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases

It also slows gastric emptying, making me feel fuller longer and reducing food intake